OPRX icon

OptimizeRx

17.12 USD
-0.21
1.21%
At close Updated Sep 15, 2:10 PM EDT
1 day
-1.21%
5 days
-7.46%
1 month
1.54%
3 months
24.33%
6 months
107.01%
Year to date
228.6%
1 year
121.47%
5 years
-15.46%
10 years
64.62%
 

About: OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.

Employees: 129

0
Funds holding %
of 7,463 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

329% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 7

147% more call options, than puts

Call options by funds: $3.09M | Put options by funds: $1.25M

65% more capital invested

Capital invested by funds: $102M [Q1] → $168M (+$66.3M) [Q2]

28% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 25

25% more funds holding

Funds holding: 87 [Q1] → 109 (+22) [Q2]

3.8% more ownership

Funds ownership: 63.47% [Q1] → 67.26% (+3.8%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$18
5% upside
Avg. target
$19
11% upside
High target
$20
17% upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
JMP Securities
Constantine Davides
$20
Market Outperform
Maintained
11 Aug 2025
Stifel
David Grossman
$18
Buy
Maintained
8 Aug 2025

Financial journalist opinion

Based on 8 articles about OPRX published over the past 30 days

Neutral
GlobeNewsWire
5 days ago
OptimizeRx to Participate in the 9th Annual Lake Street Capital Best Ideas Growth Conference
WALTHAM, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the 9th Annual Lake Street Capital Best Ideas Growth Conference taking place Thursday, September 11, 2025, in New York, NY.
OptimizeRx to Participate in the 9th Annual Lake Street Capital Best Ideas Growth Conference
Neutral
GlobeNewsWire
5 days ago
OptimizeRx Partners with Lamar Advertising to Reach Clinically Relevant Audiences Through Out-of-Home Healthcare Advertising
Strategic Partnership Combines OptimizeRx's Patented Micro-Neighborhood ® Targeting Data with Lamar's Vast Nationwide OOH Network to  Strengthen OOH Media for Healthcare Marketing
OptimizeRx Partners with Lamar Advertising to Reach Clinically Relevant Audiences Through Out-of-Home Healthcare Advertising
Positive
Zacks Investment Research
10 days ago
Best Growth Stocks to Buy for September 5th
OPRX, KT and GLDD made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 5, 2025.
Best Growth Stocks to Buy for September 5th
Positive
Zacks Investment Research
12 days ago
Best Growth Stocks to Buy for September 3rd
OPRX, PHIN and KT made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 3, 2025.
Best Growth Stocks to Buy for September 3rd
Positive
Zacks Investment Research
14 days ago
What Makes OptimizeRx Corp. (OPRX) a Strong Momentum Stock: Buy Now?
Does OptimizeRx Corp. (OPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes OptimizeRx Corp. (OPRX) a Strong Momentum Stock: Buy Now?
Positive
Zacks Investment Research
25 days ago
All You Need to Know About OptimizeRx (OPRX) Rating Upgrade to Strong Buy
OptimizeRx (OPRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
All You Need to Know About OptimizeRx (OPRX) Rating Upgrade to Strong Buy
Positive
Zacks Investment Research
25 days ago
Best Momentum Stock to Buy for August 21st
OPRX, BZ and ANET made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 21, 2025.
Best Momentum Stock to Buy for August 21st
Neutral
GlobeNewsWire
27 days ago
OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth
WALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced organizational updates and leadership advancements designed to accelerate the Company's Rule of 40 strategy—balancing sustained growth with increased profitability. These changes reflect the strength of the Company's leadership bench and CEO Steve Silvestro's commitment to aligning talent and structure with OptimizeRx's long-term strategic objectives under his management.
OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth
Neutral
Seeking Alpha
1 month ago
OptimizeRx Corporation (OPRX) Q2 2025 Earnings Call Transcript
OptimizeRx Corporation (NASDAQ:OPRX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andrew Jacob D'Silva - Senior Vice President of Corporate Finance Edward Stelmakh - CFO & COO Stephen L. Silvestro - President & CEO Conference Call Participants Anderson Schock - B.
OptimizeRx Corporation (OPRX) Q2 2025 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
OptimizeRx Corp. (OPRX) Surpasses Q2 Earnings and Revenue Estimates
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.02 per share a year ago.
OptimizeRx Corp. (OPRX) Surpasses Q2 Earnings and Revenue Estimates
Charts implemented using Lightweight Charts™